If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Reductions in the Abasaglar dose when transitioning from certain insulins will lower the likelihood of hypoglycemia.1,2
Transitioning From Another Basal Insulin to Abasaglar Therapy1,2
If transitioning from…
Then, the recommended initial dose of Abasaglar …
is the same as the Lantus dose.
50 units of Lantus transitions to 50 units of Abasaglar
is 80% of the Toujeo dose.
50 units of Toujeo transitions to 40 units of Abasaglar
twice-daily NPH insulin
is 70%-80% of the total daily NPH insulin dosage.
25 units of NPH insulin every morning and 25 units of NPH insulin every evening, for a daily total of 50 units of NPH insulin, transitions to 35 units (70% of the NPH insulin total daily dose) or 40 units (80% of the NPH insulin total daily dose) of Abasaglar once daily
an intermediate- or long-acting insulin other than Lantus
may differ from the prior basal insulin dose and other concomitant antihyperglycemic medications may need to be adjusted.